Precision medicine depends on two fundamental capabilities: understanding disease at the genomic level and identifying treatments at the molecular level.
NVIDIA’s contributions to precision medicine extend far beyond accelerated computing, delivering a full-stack platform that translates hardware and software advancements directly into healthcare outcomes.
Sequencing the human genome initially took more than a decade, and now it can be completed in a matter of hours. This dramatic shift goes beyond a technical milestone. It has enabled earlier detection, faster diagnoses, and more targeted therapies, fundamentally changing how diseases are understood and treated.
This increase in sequencing speed has shifted the genomic bottleneck from data generation to data analysis. Faster sequencing is only valuable if downstream analysis can keep pace. Clinicians need to make treatment decisions more quickly, particularly in highly time-sensitive settings such as oncology or neonatal intensive care units (NICUs), where every minute matters.
Separately, the traditional process of characterizing a protein’s structure, which is fundamental to drug development, once required years of laborious experimental work, but new AI-based methods like AlphaFold have reduced this to minutes or hours. This shift accelerates drug discovery by dramatically reducing the time and expense of identifying therapeutic candidates and enabling high-throughput screens.
